Business Description
Unipharma Co Ltd
ISIN : TW0006621006
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 8.71 | |||||
Equity-to-Asset | 0.91 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.84 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 8.35 | |||||
Beneish M-Score | -3.18 | |||||
WACC vs ROIC |
Growth Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -9.6 | |||||
3-Year EBITDA Growth Rate | 28.5 | |||||
3-Year EPS without NRI Growth Rate | 27 | |||||
3-Year Book Growth Rate | -6.5 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 67.21 | |||||
9-Day RSI | 60.9 | |||||
14-Day RSI | 55.5 | |||||
6-1 Month Momentum % | 6.04 | |||||
12-1 Month Momentum % | -9.65 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 11.05 | |||||
Quick Ratio | 9.65 | |||||
Cash Ratio | 8.4 | |||||
Days Inventory | 193.2 | |||||
Days Sales Outstanding | 71.81 | |||||
Days Payable | 85.82 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.3 | |||||
Shareholder Yield % | -1.16 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 47.09 | |||||
Operating Margin % | -32.12 | |||||
Net Margin % | -26.55 | |||||
FCF Margin % | -27.5 | |||||
ROE % | -8.54 | |||||
ROA % | -7.74 | |||||
ROIC % | -20.91 | |||||
3-Year ROIIC % | 9.63 | |||||
ROC (Joel Greenblatt) % | -65.28 | |||||
ROCE % | -8.4 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Price-to-Owner-Earnings | 51.87 | |||||
PS Ratio | 5.07 | |||||
PB Ratio | 1.65 | |||||
Price-to-Tangible-Book | 1.66 | |||||
EV-to-EBIT | -14.25 | |||||
EV-to-EBITDA | -18.86 | |||||
EV-to-Revenue | 3.78 | |||||
EV-to-FCF | -13.34 | |||||
Price-to-Projected-FCF | 3 | |||||
Price-to-Net-Current-Asset-Value | 3.14 | |||||
Price-to-Net-Cash | 4.4 | |||||
Earnings Yield (Greenblatt) % | -7.02 | |||||
FCF Yield % | -5.44 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Unipharma Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil NT$) | 99.557 | ||
EPS (TTM) (NT$) | -0.74 | ||
Beta | 0.26 | ||
Volatility % | 37.72 | ||
14-Day RSI | 55.5 | ||
14-Day ATR (NT$) | 0.509996 | ||
20-Day SMA (NT$) | 13.695 | ||
12-1 Month Momentum % | -9.65 | ||
52-Week Range (NT$) | 11.8 - 19.65 | ||
Shares Outstanding (Mil) | 35.5 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Unipharma Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Unipharma Co Ltd Stock Events
Event | Date | Price(NT$) | ||
---|---|---|---|---|
No Event Data |
Unipharma Co Ltd Frequently Asked Questions
What is Unipharma Co Ltd(ROCO:6621)'s stock price today?
When is next earnings date of Unipharma Co Ltd(ROCO:6621)?
Does Unipharma Co Ltd(ROCO:6621) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |